108 results about "Acute hepatitis" patented technology

The present invention relates to 5-thia-omega-substituted phenylprostaglandin E derivatives of the formula (I)(wherein, all the symbols are as defined in the specification), process for producing them and pharmaceutical compositions comprising them as active ingredient.The compounds of the formula (I) can bind to PGE2 receptors (especially, subtype EP4) strongly, so they are expected to be useful for prevention and/or treatment of immunological diseases (autoimmune diseases such as amyotrophic lateral sclerosis (ALS), multiple sclerosis, Sjoegren's syndrome, chronic rheumarthrosis and systemic lupus erythematosus etc., and rejection after organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, lung failure, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardiac ischemia, systemic inflammatory response syndrome, ambustion pain, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, and shock etc. Further, it is thought that EP4 subtype receptor relates to sleeping disorder and blood platelet aggregation, so the compounds of the present invention are expected to be useful for the prevention and/or treatment of such diseases.

A compound preparation consists of ornithine or its salt and asparagic acid or its salt as well as proper amount of supplementary material; and is prepared into oral preparation or injection through mechanical mixing and other process. The said compound preparation is used for treating various acute hepatitis, chronic hepatosis and hepatic encephacopathy and has the obvious effects of protecting liver and strengthening physique. The preparation process is simple, short in production period and low in cost.

The invention discloses a traditional Chinese medicine composition for treating acute hepatitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following raw medicinal herbs: radix bupleuri, folium isatidis, isatis root, chrysanthemum, taraxacum officinale root, herba violae, pericarpium citri reticulatae viride, rhizoma cyperi, costus root, hawthorn, angelica sinensis, raw rehmannia, radix scrophulariae, root of kudzu vine, radix paeoniae alba, soapstone, cape jasmine, houttuynia cordata, subprostrate sophorae, rhizoma smilacis glabrae, oriental wormwood, indigo naturalis, coptis, rheum officinale, felwort, ash bark, radix sophorae falvescentis, bunge cherry seed, lophatherum gracile, bezoar, antelope's horn, patrinia, lithospermum, moutan bark and root of common peony. The traditional Chinese medicine composition can be prepared into any one common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve symptoms of inappetence, hepatitis B virus, hepatitis B carrier, arcane positive, greasy antiposia, diarrhea, jaundice, hepatic encephalopathy, electrolyte disturbance, encephaledema, cerebral hernia, hepatorenal syndrome, hydroperitoneum, electrolyte disturbance and the like, and has accurate clinical treatment effect, remarkable treatment effect and rapid effect taking. Because of being combined by basically adopting medicinal and edible Chinese medicinal herbs specified in National Formulary, the traditional Chinese medicine composition has the advantages of low cost, basic no toxic and side effects, and the like.

The invention relates to a traditional Chinese medicine for curing hepatitis, in particular to a traditional Chinese medicine for curing acute and chronic hepatitis, belonging to the Chinese herbal medicine oral administration product field. The basic formula consists of ten Chinese herbs including angelica, artemisia capillaries, tuckahoe, radix curcumae, Japanese ardisia, white peony root, bupleurum, atractylodes rhizome, mint and glycyrrhiza. When the basic formula is applied to cure acute hepatitis, rhubarb and gardenia are added; when the basic formula is applied to cure chronic hepatitis, salvia miltiorrhiza and polygonum cuspidate are added. After compatibility of the whole formula, the herbs have synergistic effect, thus enhancing immunity of patient, generating antibody by the human body itself, killing virus and pathogen, and purifying the virus in the hepatic blood. The invention overcomes disadvantages of western medicine for curing acute and chronic hepatitis, which just addresses symptoms but not root causes and has great side effect. Treatment with the traditional Chinese medicine has advantages of short treatment cycle, little side effect, no allergic reaction, high cure rate and no recurrence thereafter. The invention is applicable in treatment of various acute and chronic hepatitis patients.

The invention relates to a pharmaceutical composition containing silybin or its salts as the active constituents, the composition also comprises water-soluble bulking agent, pH regulator, stabilizer, water for injection, and osmoregulation agent. The pH of the disclosed freeze-dried powder injection, injection and transfusion is between 7-9 under aqueous solution state, the stabilizing agent is preferably tris(hydroxymethylamino)methane. The pharmaceutical composition can be used for treating acute hepatitis.

A Chinese medicine in the form of dropping pill for treating acute and chronic hepatitides is prepared from silymarinum, polyethylene glycol and tween-80 through mixing the fused silymarium with polyethylene glycol and dripping in condensing liquid. Its advantages are high dissolving speed and biologic utilization rate.

A traditional Chinese medicine for curing acute hepatitis with jaundice belongs to a traditional Chinese medicine for curing hepatitis. The components contain: 25g of virgate wormwood herb, 15g of tuckahoe, 15g of polyporus, 15g of oriental waterplantain rhizome, 15g of largehead atractylodes rhizome, 15g of chinese thorowax root, 15g of turmeric root tuber, 30g of danshen root; the invention has the auxiliary prescriptions that: for severe heat, 20g of cape jasmine fruit, 20g of rhubarb and 20g of atrina glass are added; for severe dampness, 20g of agastache rugosa, 20g of atractylodes rhizome and 20g of roud cardamon seed are added; for static blood, 25g of red peony root, 25g of tree peony bark and 25g of peach seed are added. The substances in the prescription are made from natural traditional Chinese medicine plus traditional preparing methods. The materials are easy to collect, the prescription and the preparation methods are simple, and the cost of medicine preparation is low. The compatibility of the traditional Chinese medicine is simple; the medicine used in the prescription is fully natural herbal medicine, which is easy to collect and use; the preparation method is simple; the effects for taking and curing are good; the cost of the medicine is low, and the medicine is in particular suitable for the people living in remote villages far from towns; the cost is low for curing the people suffering from acute hepatitis with jaundice, which solves the problem that the local area lacks medical conditions to cure the disease because of low household income and poor living condition.

The invention relates to the field of drug research and development and particularly discloses an application of a compound HUBIN-1 in preparation of a drug for preventing and/or treating liver inflammatory diseases. Extensive and deep research discovers the hepatocyte protection function and the anti-inflammatory treatment function of the compound HUBIN-1 for the first time, the compound HUBIN-1 is applicable to various types of liver inflammations, and the application field of the compound HUBIN-1 is broadened. The novel drug for preventing and/or treating various liver inflammatory diseases such as acute hepatitis, chronic hepatitis and severe hepatitis (hepatic failure) which include viral hepatitis, drug-induced hepatitis, nonalcoholic fatty liver disease, alcoholic hepatitis, autoimmune hepatitis and the like is provided and has remarkable social benefits.

The invention discloses traditional Chinese medicine for treating acute hepatitis, chronic hepatitis and hepatic fibrosis. The traditional Chinese medicine is characterized in that the traditional Chinese medicine is prepared by raw materials including, by weight percentage, from 25 to 50% of total saponin of aralia taibaiensis and from 50 to 75% of total polyphenol of phyllanthus urinaria. The traditional Chinese medicine has the advantages of scientific prescription, convenience in preparation, good curative effect, safety and zero side effects.

The present invention relates to a silybin meglumine dispersing tablet for curing hepatitis and its preparation method. Said invention provides its structural formula and its molecular formula, and its composition is composed of C22H39O15N and ten auxiliary materials. Said invented dispersing tablet can be mainly used for curing acute hepatitis, chronic hepatitis, initial cirrhosis, fatty liver and protecting liver for toxic hepatic damage.

The invention relates to silibinin meglumine with high purity, the preparation method and the application in preparing the drugs for treating acute attack of acute hepatitis and chronic hepatitis and toxic liver injury, belonging to medical technical field. The content of the silibinin meglumine with high purity is more than 98% tested using HPLC, thereby the drawbacks of bad safety for clinical application and bad quality controllability due to low purity of silibinin meglumine are overcome. The invention has the advantages of high purity, good stability and safety and improved human bioavailability compared to former oral preparation since the silibinin meglumine with high purity can be used for injection preparation.

When acute hepatitis progresses to fulminant hepatitis, a large amount of hepatic cells are rapidly broken, and as a result, the prognosis is seriously worsened. Thus, it is important to prognose the progress of acute hepatitis into fulminant hepatitis at an early stage and quickly start an appropriate treatment therefor. Although the prognosis of progress into fulminant hepatitis becomes possible owing to recent advances in test methods and diagnostic techniques, there has been no appropriate prophylactic/therapeutic agent for fulminant hepatitis. The present invention provides a therapeutic agent for acute hepatitis or a prophylactic/therapeutic agent for fulminant hepatitis with little side effect. The problem of the invention was solved by using a composition containing apolipoprotein A-II.

The invention discloses a traditional Chinese medicinal composition for treatment of hepatitis. The composition consists of a Laminaria japonica Aresch extract, an Eucheuma extract, fenugreek and Geranium wilfordii. The traditional Chinese medicinal composition provided in the invention is a clinically acceptable tablet, capsule, granule, pill or oral liquid prepared by adding a conventional auxiliary material according to a conventional process. The traditional Chinese medicinal composition disclosed in the invention has liver soothing and liver protecting functions, can achieve good therapeutic effects on acute hepatitis A, acute hepatitis B, chronic persistent hepatitis and chronic active hepatitis, and also has obvious effects and no toxic or side effect.

Provided is a screening method being able to screen an agent useful for prevention and/or treatment of hepatitis C virus-related disease easily and efficiently and a prophylactic and/or therapeutic agent for hepatitis C virus-related disease obtained by the method.

The screening method for a prophylactic and/or therapeutic agent for hepatitis C virus-related disease according to the present invention is characterized by comprising a a step of examining the inhibitory activity of an test substance on the protein-protein interaction between hepatitis C virus core protein and PA28γ. The method can be carried out, for example, by using transcriptional activity of a lipid metabolism-control factor as indicator. The test substance used in the method may have an activity to inhibit expression or function of the PA28γ gene. The hepatitis C virus-related diseases include hepatitis C, fatty liver, acute hepatitis, chronic hepatitis, liver cirrhosis, liver cancer, insulin-resistant diseases, and the like. The method according to the present invention is extremely useful as a method of obtaining an agent superior in preventive and therapeutic activity particularly to diseases such as fatty liver and liver cancer.

The invention discloses a triterpenoid AntcinK and liver-protecting activity and application thereof. The triterpenoid AntcinK is extracted from wild, basswood-cultured and/or plate-cultured antrodia camphorate sporocarps, multiple activity screenings prove that the triterpenoid has the outstanding activity of protecting acute hepatitis liver damage caused by CCl4 and the activity of protecting abnormal lipid accumulation induced by alcohol. The compound has the remarkable preventing and treating effect on acute hepatitis, liver damage and alcoholic fatty liver and can be widely applied to liver protecting drugs and health-care products.

The invention provides a new hepatitis A virus JS-4 strain for preparing hepatitis A inactivated vaccine and a method for culturing the same. The strain is separated from dejecta of a patient infected with acute hepatitis A and is transmitted to a Vero cell for adapted culture; through neutralization tests and other methods, the strain is proved to be hepatitis A virus; in the adaptation process, the subculture cycle of early generation is 28 days; when the strain is transmitted to the tenth generation, the cycle is shortened to 21 days; the strain is continuously cultured for ten generations; the culture temperature is between 35 and 36 DEG C; the cycle for virus propagation is shortened from 28 to 21 days; the antigen titer can reach 1:640-1:1,280; and the infectious titer is between 106.67 and 107.50 CCID50/ml. The marmoset virulence test proves that the strain has weak virulence, is reliable in safety and has good immunogenicity and protective effect when the strain is used for producing the hepatitis A inactivated vaccine and is an ideal strain for producing the hepatitis A inactivated vaccine.

The invention belongs to the chemical medicine technical field, and particularly relates to a bifendate derivative containing halogen substituent, a preparation method and an application of the bifendate derivative for treating autoimmune disease. AA structure of the bifendate derivative containing halogen substituent is shown as a formula I, the experiments prove that the bifendate derivative containing halogen substituent shown in the formula I has good effect for treating autoimmune disease, and the bifendate derivative containing halogen substituent has the effect for inhibiting autoimmune diseases such as acute hepatitis, chronic hepatic fibrosis or pulmonary fibrosis, and provides a new selection for medicament exploitation for treating diseases.

The invention discloses use of a PAPP inhibitor Talazoparib or salt and solvate thereof in the preparation of drugs for treating or preventing diseases related with hepatitis virus. The diseases are infected by hepatitis B virus, are related with the infection of the hepatitis B virus and include acute hepatitis, chronic hepatitis, hepatic fibrosis, liver cirrhosis, liver cancer or cholangiocellular carcinoma and the like; by utilizing a Talazoparib single drug or combining the Talazoparib single drug with other anticancer drugs, host cells of the hepatitis B virus can be effectively eliminated, and the growth of positive cancer cells of the hepatitis B virus can be effectively inhibited; and compared with other types of PARP inhibitors such as Olaparib, Talazoparib has obvious advantageson the dosage and the treatment effect that: Talazoparib can be used for relatively effectively controlling the infection of the hepatitis B virus, inhibiting the development of positive cancers of the hepatitis B virus and relatively effectively controlling the proliferation of the positive cancers, with relatively large volume (not smaller than 400mm<3>) of the hepatitis B virus in a relativelylater period in a relatively low dosage range (0.015mg/kg/d-0.275mg/kg/d and is a unique anti-cancer drug for healing the type of tumors at present.

A Chinese traditional medicine for curing infantile acute hepatitis belongs to a Chinese traditional medicine for curing hepatitis. The ingredients of the medicine are 30g of virgate wormwood herb, 30g of dyers woad roots, 15g of Chinese rhubarb, 15g of ardisia herb, 15g of plantain seeds, 15g of root of red salvia, 10g of pittosporm root and 10g of fried germinated millet; the auxiliary ingredients are 25g of stringy stonecrop herb and 25g of subprostrate soplhor roots under the situation of more than 200 units of aminotransferase; 20g of herb of christina losesetrife and 20g of red peony roots under the situation of serious jaundice; 18g of forsythia and 18g of scutellaria roots under the situation of fever; 10g of perilla stem and 10g of coptis. The medicines used in the prescription are all natural herbs and the Chinese traditional medicine is processed with traditional method; the fetching of material is convenient and the prescription and manufacture method are simple; the expense for manufacturing the medicine is low. The composition of the Chinese herbal medicine is simple and the medicines used in the prescription are all natural ones and the fetching and use are convenient; the manufacture method is simple and the effect is excellent; the price is low; in this way, the herbal medicine is especially fit for people living in remote villages far away from counties and towns; the curing expense for patients with the disease of infantile acute hepatitis is low which solves the problem that the household income is low and the life is poor and the medical conditions is deficient locally.

The invention discloses a traditional Chinese medicine formula for treating acute hepatitis. The traditional Chinese medicine formula comprises the following traditional Chinese medicine components in parts by weight: 10g of radix bupleuri, 15g of common turmeric, 15g of angelica sinensis, 15g of radix paeoniae alba, 20g of salvia miltiorrhiza, 20g of codonopsis pilosula, 10g of atractylodes macrocephala, 15g of poria cocos, 20g of medicated leaven and 10g of licorice. A preparation and use method of the traditional Chinese medicine formula disclosed by the invention comprises the following steps: respectively weighing the ten medicines of radix bupleuri, common turmeric, angelica sinensis, radix paeoniae alba, salvia miltiorrhiza, codonopsis pilosula, atractylodes macrocephala, poria cocos, medicated leaven and licorice according to the parts by weight, boiling with water which is 5 times the weight of the medicines, decocting for 1 hour with strong fire firstly, further decocting for 1 hour with soft fire, cooling, filtering, abandoning medicine dregs, and bottling according to the dosage of 150ml, thereby obtaining a traditional Chinese medicine finished product for treating the acute hepatitis. The medicine is orally taken three times a day, 50ml of the decoction is taken each time, and one treat course lasts for 10 days. The acute hepatitis can be cured within one treatment course, chronic active hepatitis and chronic persistent hepatitis can be cured within two to three treatment courses, and chronic hepatitis B can be cured within 3-6 months.

The present invention belongs to the field of Chinese medicine technology and organic synthesis technology. Oleanolic acid as one natural Chinese medicine component and succinic anhydride in the amount of 7 times produce esterification reaction under the catalysis of anhydrous pyridine in 4 times at 100 deg.c for 8 hr to produce succinyl oleanolic acid monoester with new chemical structure. After reaction, the product is water washed to eliminate residual succinic anhydride and pyridine and further purified through re-crystallization in anhydrous ethanol. The obtained new compound has molecular expression of C34H52O6, molecular weight of 556.77 and melting point of 256-258 deg c. By means of the structural modification, the present invention has raised water solubility and dispersivity and raised bioavailability. The product of the present invention is orally taken to treating acute and chronic liver damage, lower transaminase, reduce liver fibrosis and inhibit immunological liver pathologic changes.

The invention relates to a liver protecting and calming pill which has the efficacy of clearing heat and promoting diuresis, benefiting liver and removing blood stasis, soothing liver and relieving pain, removing jaundice and lowering glutamic-pyruvic transaminase, and is suitable for treating acute hepatitis and chromic hepatitis and the active components of which consists of the medicinal materials of stringy stonecrop, giant knotweed, red sage root and ganoderma lucidum, and a preparation method thereof. The liver protecting and calming pill prompts an organism to play the normal immunologic role, start a liver self-healing system, block autoimmune reaction and strength physique and anti-virus ability; recovers the normal detoxification function of the liver to cause normal operation of human body; resists liver damage to effectively inhibit the increase of serum glutamic-pyruvic transaminase (SGPT), serum glutamic-oxaloacetic transaminase (SGOT) and lactate dehydrogenase (LDH); and increases hemoglobin to obviously increase the Hb content of blood plasma. The liver protecting and calming pill keeps stable blood-drug level and fully play the drug effect according to the theory of long-term administration for liver disease and the 'sluggish characteristic of pills' .

The present invention relates to capillary artemisia dripping pill for treating acute hepatitis, chronic hepatitis, hepatitis B, chronic cholecystitis and other diseases and its preparation process. The present invention includes the recipe and preparation process of capillary artemisia dripping pill and the extracting process of capillary artemisia extract. The capillary artemisia dripping pill is or is not coated.

The invention discloses application of a eukaryotic peptide chain release factor 3b fragment 36 (eRF3b-36) in the treatment of liver injury. The invention discloses application of the eRF3b-36 in the preparation of products for preventing and/or treating liver injury. According to the application, the eRF3b-36 has a good prevention and treatment effect on Con A induced acute hepatitis; in addition, shown by treatment research on fatty liver, dosed groups of the eRF3b-36 exert a good protecting effect on the liver regardless of whether in a serological index or hepatic histopathology, the level of ALT, AST, CHOL, TG and TBIL in blood serum can be remarkably lowered, and the content of free fat in liver tissue can be lowered; thus, a new possible direction and specific measures are provided for clinical liver disease treatment.

The invention discloses a traditional Chinese medicine combination for hepatopathy treatment, which includes the following active ingredients (by weight part): 0.10-0.20 part of toad, 0.02-0.07 part of scutellaria barbata, 0.02-0.07 part of salvia chinensis, 0.02-0.07 part of serissa serissoide and 0.02-0.07 part of tarragon. The traditional Chinese medicine combination for hepatopathy treatment has the characteristics of warm nature, bitterness, slight pungency, liver soothing, fever reducing and diuresis. The traditional Chinese medicine combination is used for the treatment of hepatitis, cirrhosis, jaundice hepatitis, acute hepatitis, infectious hepatitis, liver ascites, and positive HBV and the like; meanwhile, the traditional Chinese medicine combination has the efficacies of invigorating blood circulation, removing stasis, invigorating pulse and meridians and collaterals, inhibiting platelet aggregation and enhancing cerebral blood flow, has special good efficacy on cerebral collateral stasis, stroke paralysis, heart vessel stasis, chest obstruction and pain, coronary heart disease, angina and hypertension, and hyperlipidemia.